ARCHIVES

FDA Consider Regulation of CME Programs Paid for By Drug Companies; Goal To Limit Promotion

This article is from The Cancer Letter archive.

Vol. 18 No. 01 | January 3, 1992

Download PDF Visit The Full Archive

Related Articles

Laertrile Clinical Study Provides Solid Evidence: It Is Useless

May 8, 1981

UICC Seeks Nominations for Mucio Athayde Prize.

January 7, 2000

Obituary: Selma Schimmel, Founder of Vital Options, Dies of Cancer

May 23, 2014

European Agency Recommends Transfusions Over ESAs For Cancer Patients With Longer Life Expectancy.

June 27, 2008

NCI Clarifies P01 Grant Application Dates

September 13, 1996

The Raghavan Experiment: With $500 Million to Draw On, An Iconoclast Invents Rational Care for a Gigantic System

January 4, 2013